Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3687012 | 0.83 | MGAM (0.36) | CA1CA2MGAMGAASI | |
| SCHEMBL8357552 | 0.81 | SMN1; SMN2 (0.35) | CA1CA2MGAMGAASI | |
| SCHEMBL3686978 | 0.79 | CA1 (0.43) | CA1CA2KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL7977852 | 0.78 | SMN1; SMN2 (0.38) | CA1CA2MGAMGAASI | |
| SCHEMBL188112 | 0.78 | SMN1; SMN2 (0.38) | CA1CA2MGAMGAASI | |
| SCHEMBL4570452 | 0.77 | ALDH1A1 (0.37) | CA1CA2MGAMGAASI | |
| SCHEMBL14942765 | 0.77 | CA2 (0.61) | CA1CA2MGAMGAASI | |
| SCHEMBL7745289 | 0.76 | EPHX1 (0.32) | CA1CA2MGAMGAASI | |
| SCHEMBL7750328 | 0.75 | ALDH1A1 (0.32) | CA1CA2MGAMGAASI | |
| SCHEMBL6437698 | 0.74 | MGAM (0.43) | CA1CA2MGAMGAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2060557-B1 | Intermediate compounds useful to prepare dolasetron | INKE SA (ES) | 2012-06-06 | — | — | EP | disclosed |
| EP-2060557-B1 | Intermediate compounds useful to prepare dolasetron | INKE SA (ES) | 2012-06-06 | — | — | EP | disclosed |
| US-7858821-B2 | Intermediate compounds useful to prepare dolasetron | INKE, S.A. (ES) | 2010-12-28 | — | — | US | disclosed |
| US-7858821-B2 | Intermediate compounds useful to prepare dolasetron | INKE, S.A. (ES) | 2010-12-28 | — | — | US | disclosed |
| EP-2060557-A1 | Intermediate compounds useful to prepare dolasetron | INKE, S.A. (ES) | 2009-05-20 | — | — | EP | disclosed |
| EP-2060557-A1 | Intermediate compounds useful to prepare dolasetron | INKE, S.A. (ES) | 2009-05-20 | — | — | EP | disclosed |
| US-20090124807-A1 | INTERMEDIATE COMPOUNDS USEFUL TO PREPARE DOLASETRON | INKE, S.A. | 2009-05-14 | — | — | US | disclosed |
| US-20090124807-A1 | INTERMEDIATE COMPOUNDS USEFUL TO PREPARE DOLASETRON | INKE, S.A. | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124807-A1 | INTERMEDIATE COMPOUNDS USEFUL TO PREPARE DOLASETRON | DHPS, ALG8, DDOST | CA1 2468/4885CA2 1514/4885MGAM 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.